Reflex medical device application used for opiate withdrawal studies, military concussions

0

Tool from tech company Brightlamp is being used in clinical studies funded by the NIH and DOD

WEST LAFAYETTE, Ind. – Third-party research groups and organizations have validated a smartphone app called Reflex as a tool to help diagnose medical conditions like concussions and opiate withdrawal.

Brightlamp CEO Kurtis Sluss said Reflex has been used in over 200 clinics, with over 90,000 tests administered to date. More than 30,000 patients have benefited from Reflex’s rapid neurological assessment. Brightlamp marketed the app.

Reflex is an autonomic vital signs assessment tool rooted in pupillometry, the measurement of the amount and rate at which the size of the eye’s pupil changes in response to a stimulus. The tool uses a digital video recording of the eye to measure a response called the pupillary light reflex. The user holds the camera in front of the eye and presses the smartphone screen, and a light flashes to initiate a pupil response. Reflex is a Class I 510(k) exempt regulated medical device, according to the United States Food and Drug Administration.

Sluss said OpiAIDa data science company, has independently determined that Reflex is a predictor of opioid withdrawal, which could be used to combat the opioid epidemic in the United States

“As part of a National Institutes of Health-funded study, clinical researchers rigorously evaluated Reflex to determine its effectiveness as a stand-alone, combined assessment for opioid addiction,” Sluss said. “Reflex will help responders in the opioid epidemic retrieve fast, reliable and accurate information. Now, addiction recovery specialists can access this cognitive biomarker to better understand and optimize addiction recovery. »

Christopher Evonko, coordinator of the OpiAID research study and a doctoral student in the Department of Psychology at the University of North Carolina at Wilmington, said pupillometry measurements obtained from Reflex outperformed self-report measurements and observational standard in a study to assess the assessment of opioid withdrawal. Evonko said the metric was significantly associated with the time since a patient’s last opioid dose.

“Accurate and reliable quantification of opioid withdrawal is critically important in guiding dosing decisions in the delivery of medically assisted treatments for opioid use disorder,” Evonko said. “The Reflex app addresses the accessibility issue of traditional pupillometry equipment and has the potential to positively impact the opioid pandemic by providing clinicians with actionable data to improve patient retention and ultimately account, the results of the treatment.”

Sluss said clinical results have also shown Reflex to be useful in diagnosing concussions as part of a Study published in 2021, with independent and validating research presented in 2022.

“This prompted medical researchers at the University of Maryland, in partnership with the US Department of Defense, to use Reflex in a two-year clinical trial to evaluate 1,200 soldiers with brain injuries,” Sluss said.

“Reflex has been named by researchers at the University of Maryland as the highest-scoring clinical decision support tool among many other leading concussion tools on the market. This preliminary assessment indicates just how powerful Reflex can be in a military context.

Sluss said more third-party studies are underway, opening up a range of opportunities for Reflex users.

“Our goal is to become the standard cognitive health screening tool, regardless of disease,” Sluss said. “These parallel studies show positive results and prove what we already knew: the eyes are a critical entry point for managing brain-related injuries and diseases.”

Brightlamp has opened up investments in its company through StartEngine, a regulated crowdfunding organization, to support the next wave of Reflex developments and market advancements. The campaign is available online at http://www.startengine.com/reflex.

Brightlamp’s plan for Reflex is to continue to improve data interpretation for clinical decision support based on independent data published by Reflex users.

“We’ve built a great Reflex community, and we’re collectively excited about the usefulness of this easy-to-use medical app,” Sluss said.

Sluss received marketing advice from Purdue Foundry, a hub for entrepreneurship and commercialization housed in the Convergence Center for Innovation and Collaboration in Purdue’s Discovery Park District, located adjacent to the Purdue University campus. His company is now part of Purdue Foundry’s Double Down experience, which includes high-growth businesses.

About Brightlamp

Brightlamp is an Indiana-based health technology company that specializes in cutting-edge computer vision methods. Recognized by experts, such as Donald Kuratko of Indiana University, the company develops innovative neurological breakthrough methods and applies them to mobile solutions to help advance cognitive healthcare.

Brightlamp’s first patented technology monitors the eye’s reaction to light so healthcare professionals can get more accurate and consistent neurological information in seconds via a mobile device. The iPhone and iPad names are trademarks of Apple Inc. For more information, visit https://reflexapp.io/.

About the Purdue Foundry

The Purdue Foundry is an entrepreneurship and commercialization center whose professionals help Purdue innovators build startups. The Purdue Foundry is operated by the Purdue Research Foundation, which received the 2019 Innovation and Economic Prosperity Universities Award for Place from the Association of Public and Land-grant Universities. Contact the Purdue Foundry at [email protected]

Writer/media contact: Steve Martin, [email protected]

Sources: Kurtis Sluss, [email protected]

Christopher Evonko, [email protected]

Share.

About Author

Comments are closed.